WO2004060279A2 - Use of silver sulfadiazine for viral aliments, and preparations and combinations therefor - Google Patents
Use of silver sulfadiazine for viral aliments, and preparations and combinations therefor Download PDFInfo
- Publication number
- WO2004060279A2 WO2004060279A2 PCT/US2003/038880 US0338880W WO2004060279A2 WO 2004060279 A2 WO2004060279 A2 WO 2004060279A2 US 0338880 W US0338880 W US 0338880W WO 2004060279 A2 WO2004060279 A2 WO 2004060279A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- viral
- ailment
- silver sulfadiazine
- heφes
- strength
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
Definitions
- This invention relates generally to the treatment of viral ailments manifesting through a patient's skin, and particularly, to the use of Silver Sulfadiazine to treat such ailments
- Silver Sulfadiazine chemically illustrated in Figure 1, was first patented by Charles L Fox, Jr on September 25, 1973, in U S Patent 3,761 ,590
- This invention of Silver Sulfadiazine combined two previously- known antibacterial agents for burns, silver nitrate and sulfadiazine, to create a synergistic compound that is extremely effective against infection
- Silver Sulfadiazine which is a broad-spectrum antimicrobial agent with bactericidal activity against most g+ and g- bacteria as well as yeast, has been used particularly for the treatment of burns
- burn patients frequently die of infections following sever burning, rather than the burns themselves
- Silver Sulfadiazine acting as a topical antibiotic, has been very effective for controlling bacterial and fungal infections following burns, by directly killing the bacteria or fungus
- Silver Sulfadiazine as a pharmaceutical product, is prepared exclusively at a strength of 1% Because pharmaceutical protocols require use of medicinal compounds at the minimum strength required to be medically effective, this means that Silver Sulfadiazine distributed at less than 1% strength would not be effective against the bacterial and fungal ailments for which it is used and there would thus be no motivation to prepare a lesser strength compound absent the discovery of some other uses not yet known in the prior art
- Silver Sulfadiazine it would be desirable to treat viral ailments manifesting on a patient's skin, such as herpes, fever blisters, cold sores, Chicken Pox, and genital and other warts, in a manner as simply and effectively as Silver Sulfadiazine is used to treat burns It would also be desirable to employ Silver Sulfadiazine at a strength of less than 1%, if it can be effective at such lesser strengths against ailments for which it has not been heretofore used
- the invention disclosed comprises novel and inventive uses of Silver Sulfadiazine, and associated preparations and combinations These include a method of treating a viral ailment, comprising the step of applying Silver Sulfadiazine proximate a site upon a person's skin where said viral ailment is manifest, using Silver Sulfadiazine to treat a viral ailment, and distributing Silver Sulfadiazine to treat a viral ailment Also disclosed is a medically-prescriptive combination for treating a viral ailment, comprising Silver Sulfadiazine, and instructions to use said Silver Sulfadiazine to treat a viral ailment Further disclosed is Silver Sulfadiazine prepared at various strengths of less than 1%, as well as preparing Silver Sulfadiazine at various strengths of less than 1% These strengths may be suitable for the viral ailments disclosed, although they are not strong enough for bacterial and fungal ailments for which Silver Sulfadiazine is ordinarily used Brief Description of the Drawings
- FIG 1 illustrates the chemical structure of Silver Sulfadiazine as known in the prior art.
- Figure 2 schematically illustrates the application of Silver Sulfadiazine to a variety of viral ailments manifested on the epidermal layer of a patient's body.
- Silver Sulfadiazine is generally known to be effective in the topical treatment of bacterial and fungal infections, particularly in connection with severe burns, it turns out in accordance with the invention, following preliminary experimental testing, that it is also effective in treating the following viral ailments: 1) He ⁇ es 1 (Fever Blisters & Cold Sores); 2) He ⁇ es II (Oral and Vaginal / Genital); 3) He ⁇ es Zoster (Shingles); 4) Chicken Pox; and 5) Genital Warts. These uses of Silver Sulfadiazine appear to be novel and inventive over the prior art.
- FIG. 2 schematically illustrates the application of Silver Sulfadiazine to treat skin-layer symptoms of the above-noted viral ailments.
- this application is topical, with the Silver Sulfadiazine delivered via a cream. All suitable bases ordinarily used for prevention and treatment of bacterial and fungal superinfection may also be employed for antiviral treatments.
- this application may be non-topical, via a suitable means for non- topical delivery.
- Silver Sulfadiazine is ineffective against bacterial and fungal infections at less than 1% strength.
- Silver Sulfadiazine may be effective against the aforementioned viral ailments at a lower strength of .9%, .7%, .5%, and even .3%, in contrast to the 1% strength required to treat bacterial and fungal ailments. Only once it is known that a strength less than 1% is effective for manifestations of viral ailments, would there be any motivation to prepare Silver Sulfadiazine at such a lesser strength.
- Silver Sulfadiazine is known to treat effectively but only at 1% or greater strength, and given the absence of the above-disclosed viral treatments in the prior art, it is also novel and inventive to prepare Silver Sulfadiazine with the above-noted strengths under 1%.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Novel and inventive uses of Silver Sulfadiazine are disclosed, as well as associated preparations and combinations. These include: a method of treating a viral ailment, comprising the step of: applying Silver Sulfadiazine proximate a site upon a person’s skin where said viral ailment is manifest; using Silver Sulfadiazine to treat a viral ailment; and distributing Silver Sulfadiazine to treat a viral ailment. Also disclosed is a medically-prescriptive combination for treating a viral ailment, comprising: Silver Sulfadiazine, and instructions to use said Silver Sulfadiazine to treat a viral ailment. Further disclosed is Silver Sulfadiazine, prepared at various strengths of less than 1%, as well as preparing Silver Sulfadiazine at various strengths of less than 1%. These strengths may be suitable for the viral ailments disclosed, although they are not strong enough for bacterial and fungal aliments for which Silver Sulfadiazine is ordinarily used.
Description
Use of Silver Sulfadiazine for Viral Ailments, and Preparations and Combinations Therefor
Field of the Invention
This invention relates generally to the treatment of viral ailments manifesting through a patient's skin, and particularly, to the use of Silver Sulfadiazine to treat such ailments
Background of the Invention
Silver Sulfadiazine, chemically illustrated in Figure 1, was first patented by Charles L Fox, Jr on September 25, 1973, in U S Patent 3,761 ,590 This invention of Silver Sulfadiazine combined two previously- known antibacterial agents for burns, silver nitrate and sulfadiazine, to create a synergistic compound that is extremely effective against infection
For many years, Silver Sulfadiazine, which is a broad-spectrum antimicrobial agent with bactericidal activity against most g+ and g- bacteria as well as yeast, has been used particularly for the treatment of burns In particular, burn patients frequently die of infections following sever burning, rather than the burns themselves Silver Sulfadiazine, acting as a topical antibiotic, has been very effective for controlling bacterial and fungal infections following burns, by directly killing the bacteria or fungus
Over the years, Silver Sulfadiazine has occasionally been applied in other ways, but always to kill bacterial or fungal infections Thus, for example, catheters impregnated with chlorhexidine-silver sulfadiazine are commercially available to prevent lntravascular catheter-related infections associated with central venous catheters (Mermel, Leonard A , New Technologies to Prevent lntravascular Catheter-Related Bloodstream Infections, CDC Emerging Infectious Diseases, Vol 7, No 2, March-April 2001, pp 197-199 )
Silver Sulfadiazine, as a pharmaceutical product, is prepared exclusively at a strength of 1% Because pharmaceutical protocols require use of medicinal compounds at the minimum strength required to be medically effective, this means that Silver Sulfadiazine distributed at less than 1% strength would not be effective against the bacterial and fungal ailments for which it is used and there would thus be no motivation to prepare a lesser strength compound absent the discovery of some other uses not yet known in the prior art
It would be desirable to treat viral ailments manifesting on a patient's skin, such as herpes, fever blisters, cold sores, Chicken Pox, and genital and other warts, in a manner as simply and effectively as Silver Sulfadiazine is used to treat burns It would also be desirable to employ Silver Sulfadiazine at a strength of less than 1%, if it can be effective at such lesser strengths against ailments for which it has not been heretofore used
Summary of the Invention
The invention disclosed comprises novel and inventive uses of Silver Sulfadiazine, and associated preparations and combinations These include a method of treating a viral ailment, comprising the step of applying Silver Sulfadiazine proximate a site upon a person's skin where said viral ailment is manifest, using Silver Sulfadiazine to treat a viral ailment, and distributing Silver Sulfadiazine to treat a viral ailment Also disclosed is a medically-prescriptive combination for treating a viral ailment, comprising Silver Sulfadiazine, and instructions to use said Silver Sulfadiazine to treat a viral ailment Further disclosed is Silver Sulfadiazine prepared at various strengths of less than 1%, as well as preparing Silver Sulfadiazine at various strengths of less than 1% These strengths may be suitable for the viral ailments disclosed, although they are not strong enough for bacterial and fungal ailments for which Silver Sulfadiazine is ordinarily used
Brief Description of the Drawings
The features of the invention believed to be novel are set forth in the appended claims. The invention, however, together with further objects and advantages thereof, may best be understood by reference to the following description taken in conjunction with the accompanying drawing(s) summarized below.
Figure 1 illustrates the chemical structure of Silver Sulfadiazine as known in the prior art.
Figure 2 schematically illustrates the application of Silver Sulfadiazine to a variety of viral ailments manifested on the epidermal layer of a patient's body.
Detailed Description
While Silver Sulfadiazine is generally known to be effective in the topical treatment of bacterial and fungal infections, particularly in connection with severe burns, it turns out in accordance with the invention, following preliminary experimental testing, that it is also effective in treating the following viral ailments: 1) Heφes 1 (Fever Blisters & Cold Sores); 2) Heφes II (Oral and Vaginal / Genital); 3) Heφes Zoster (Shingles); 4) Chicken Pox; and 5) Genital Warts. These uses of Silver Sulfadiazine appear to be novel and inventive over the prior art.
Figure 2 schematically illustrates the application of Silver Sulfadiazine to treat skin-layer symptoms of the above-noted viral ailments. Preferably, this application is topical, with the Silver Sulfadiazine delivered via a cream. All suitable bases ordinarily used for prevention and treatment of bacterial and fungal superinfection may also be employed for antiviral treatments. Alternatively, this application may be non-topical, via a suitable means for non- topical delivery.
As noted earlier, Silver Sulfadiazine is ineffective against bacterial and fungal infections at less than 1% strength. In preliminary testing, it appears that Silver Sulfadiazine may be effective against the aforementioned viral ailments at a lower strength of .9%, .7%, .5%, and even .3%, in contrast to the 1% strength required to treat bacterial and fungal ailments. Only once it is known that a strength less than 1% is effective for manifestations of viral ailments, would there be any motivation to prepare Silver Sulfadiazine at such a lesser strength. Thus, given the bacterial and fungal ailments which Silver Sulfadiazine is known to treat effectively but only at 1% or greater strength, and given the absence of the above-disclosed viral treatments in the prior art, it is also novel and inventive to prepare Silver Sulfadiazine with the above-noted strengths under 1%.
While only certain preferred features of the invention have been illustrated and described, many modifications, changes and substitutions will occur to those skilled in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
Claims
We claim: 1. A method of treating a viral ailment, comprising the step of: applying Silver Sulfadiazine to a person's skin where said viral ailment is manifest.
2. The method of claim 1, said viral ailment consisting of Heφes I.
3. The method of claim 2, said Heφes I consisting of at least one fever blister.
4. The method of claim 2, said Herpes I consisting of at least one cold sore.
5. The method of claim 1, said viral ailment consisting of Heφes II.
6. The method of claim 5, said Heφes II manifested orally.
7. The method of claim 5, said Heφes II manifested vaginally.
8. The method of claim 5, said Heφes II manifested genitally.
9. The method of claim 1, said viral ailment consisting of Heφes Zoster.
10. The method of claim 1, said viral ailment consisting of Chicken Pox.
11. The method of claim 1, said viral ailment consisting of at least one genital wart.
12. Using Silver Sulfadiazine to treat a viral ailment.
13. The use of claim 12, said viral ailment consisting of Heφes I.
14. The use of claim 13, said Heφes I consisting of at least one fever blister.
15. The use of claim 13, said Heφes I consisting of at least one cold sore.
16. The use of claim 12, said viral ailment consisting of Heφes II.
17. The use of claim 16, said Heφes II manifested orally.
18. The use of claim 16, said Heφes II manifested vaginally.
19. The use of claim 16, said Heφes II manifested genitally.
20. The use of claim 12, said viral ailment consisting of Heφes Zoster.
21. The use of claim 12, said viral ailment consisting of Chicken Pox.
22. The use of claim 12, said viral ailment consisting of at least one genital wart.
23. A method of treating a viral ailment, comprising the step of: distributing Silver Sulfadiazine to treat said viral ailment.
24. The method of claim 23, said viral ailment consisting of Herpes I.
25. The method of claim 24, said Heφes I consisting of at least one fever blister.
26. The method of claim 24, said Heφes I consisting of at least one cold sore.
27. The method of claim 23, said viral ailment consisting of Heφes II.
28. The method of claim 27, said Heφes II manifested orally.
29. The method of claim 27, said Heφes II manifested vaginally.
30. The method of claim 27, said Herpes II manifested genitally.
31. The method of claim 23, said viral ailment consisting of Heφes Zoster.
32. The method of claim 23, said viral ailment consisting of Chicken Pox.
33. The method of claim 23, said viral ailment consisting of at least one genital wart.
34. A medically-prescriptive combination for treating a viral ailment, comprising: Silver Sulfadiazine; and instructions to use said Silver Sulfadiazine to treat a viral ailment. 35. The combination of claim 34, said viral ailment consisting of Heφes I. 36. The combination of claim 35, said Heφes I consisting of at least one fever blister. 37. The combination of claim 35, said Heφes I consisting of at least one cold sore.
38 The combination of claim 34, said viral ailment consisting of Heφes II 39 The combination of claim 38, said Heφes II manifested orally 40 The combination of claim 38, said Heφes II manifested vaginally 41 The combination of claim 38, said Heφes II manifested genitally 42 The combination of claim 34, said viral ailment consisting of Herpes Zoster 43 The combination of claim 34, said viral ailment consisting of Chicken Pox 44 The combination of claim 34, said viral ailment consisting of at least one genital wart 45 Silver Sulfadiazine, wherein said Silver Sulfadiazine is prepared at a strength of less than 1% 46 The Silver Sulfadiazine of claim 45, prepared at a strength of 9% or less 47 The Silver Sulfadiazine of claim 45, prepared at a strength from 3% to 9% 48 The Silver Sulfadiazine of claim 45, prepared at a strength of 7% or less 49 The Silver Sulfadiazine of claim 45, prepared at a strength from 3% to 7% 50 The Silver Sulfadiazine of claim 45, prepared at a strength of 5% or less 51 The Silver Sulfadiazine of claim 45, prepared at a strength from 3% to 5% 52 The Silver Sulfadiazine of claim 45, prepared at a strength of 3% or less 53 The Silver Sulfadiazine of claim 45, prepared at a strength of approximately 9% 54 The Silver Sulfadiazine of claim 45, prepared at a strength of approximately 7% 55 The Silver Sulfadiazine of claim 45, prepared at a strength of approximately 5% 56 The Silver Sulfadiazine of claim 45, prepared at a strength of approximately 3% 57 A method of making a composition to treat a viral ailment, comprising the step of preparing Silver Sulfadiazine at a strength of less than 1 % 58 The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength of 9% or less 59 The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength from 3% to 9% 60 The method of claim 57 further comprising the step of preparing said Silver Sulfadiazine at a strength of 7% or less 61 The method of claim 57 further comprising the step of preparing said Silver Sulfadiazine at a strength from 3% to 7% 62 The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength of 5% or less 63 The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength from 3% to 5% 64 The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength of 3% or less 65 The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength of approximately 9% 66 The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength of approximately 7% 67 The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength of approximately 5%
68. The method of claim 57, further comprising the step of preparing said Silver Sulfadiazine at a strength of approximately .3%.
69. A composition to treat a viral ailment, comprising:
Silver Sulfadiazine at a strength effective for treating said viral ailment.
70. The combination of claim 69, said viral ailment consisting of Heφes I.
71. The combination of claim 70, said Heφes I consisting of at least one fever blister.
72. The combination of claim 70, said Heφes I consisting of at least one cold sore.
73. The combination of claim 69, said viral ailment consisting of Heφes II.
74. The combination of claim 73, said Heφes II manifested orally.
75. The combination of claim 73, said Heφes II manifested vaginally.
76. The combination of claim 73, said Heφes II manifested genitally.
77. The combination of claim 69, said viral ailment consisting of Heφes Zoster.
78. The combination of claim 69, said viral ailment consisting of Chicken Pox.
79. The combination of claim 69, said viral ailment consisting of at least one genital wart.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003297704A AU2003297704A1 (en) | 2003-01-02 | 2003-12-08 | Use of silver sulfadiazine for viral aliments, and preparations and combinations therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43750003P | 2003-01-02 | 2003-01-02 | |
| US60/437,500 | 2003-01-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004060279A2 true WO2004060279A2 (en) | 2004-07-22 |
| WO2004060279A3 WO2004060279A3 (en) | 2005-03-17 |
Family
ID=32713191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2003/038880 WO2004060279A2 (en) | 2003-01-02 | 2003-12-08 | Use of silver sulfadiazine for viral aliments, and preparations and combinations therefor |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003297704A1 (en) |
| WO (1) | WO2004060279A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0287204A2 (en) * | 1987-02-25 | 1988-10-19 | The Trustees of Columbia University in the City of New York | Silver sulfadiazine useful for inhibiting the transmission of the aids virus |
| EP0355009A1 (en) * | 1988-08-18 | 1990-02-21 | Konrad Minninger | Silver sulfadiazine containing pharmaceutical product for the local external therapy |
| US5679337A (en) * | 1991-06-14 | 1997-10-21 | Professional Pharmaceutical, Inc. | Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient |
-
2003
- 2003-12-08 AU AU2003297704A patent/AU2003297704A1/en not_active Abandoned
- 2003-12-08 WO PCT/US2003/038880 patent/WO2004060279A2/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0287204A2 (en) * | 1987-02-25 | 1988-10-19 | The Trustees of Columbia University in the City of New York | Silver sulfadiazine useful for inhibiting the transmission of the aids virus |
| EP0355009A1 (en) * | 1988-08-18 | 1990-02-21 | Konrad Minninger | Silver sulfadiazine containing pharmaceutical product for the local external therapy |
| US5679337A (en) * | 1991-06-14 | 1997-10-21 | Professional Pharmaceutical, Inc. | Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient |
Non-Patent Citations (1)
| Title |
|---|
| TOKUMARU, T ET AL.: 'Antiviral Activities of Silver Sulfadiazine in Ocular Infection' RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY vol. 8, no. 1, May 1974, pages 151 - 158, XP008042970 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003297704A1 (en) | 2004-07-29 |
| WO2004060279A3 (en) | 2005-03-17 |
| AU2003297704A8 (en) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spelman | Fusidic acid in skin and soft tissue infections | |
| US4797392A (en) | Use of anorectal compositions | |
| US6555125B2 (en) | Lesion and ulcer medication | |
| KR20150113035A (en) | Compositions and methods for treating surface wounds | |
| US6352711B1 (en) | Lesion and ulcer medication | |
| Elston | Topical antibiotics in dermatology: emerging patterns of resistance | |
| WO2002094179A2 (en) | Novel topical microbicidal compositions | |
| JP2002526407A5 (en) | ||
| WO2003018049A3 (en) | Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection | |
| US6432935B1 (en) | Pharmaceutical compositions, mainly vaginal suppository, containing many different active ingredients | |
| EP2508231A2 (en) | Imidazoles for treating multi-drug resistant bacterial infections | |
| EP3210619A2 (en) | Topical formulation for treating skin or mucosal infections, preparation method and uses thereof | |
| WO2004060279A2 (en) | Use of silver sulfadiazine for viral aliments, and preparations and combinations therefor | |
| SAMS et al. | Topical treatment with sulfathiazole | |
| Mishra et al. | Topical antibiotics and semisolid dosage forms | |
| JPH0491036A (en) | External preparation for anus | |
| WO2000015207A3 (en) | Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) | |
| Carruthers | Prescribing antibiotics for impetigo | |
| CN111150738A (en) | External medicine for treating skin diseases | |
| US6838480B1 (en) | Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof | |
| JPH06505733A (en) | Use of benzimidazole anthelmintics in the treatment of microsporidiosis | |
| Seifert | Drugs for Cancer and for Autoimmune and Infectious Diseases | |
| CA2515259A1 (en) | Use of acetylsalicylic acid for the treatment of hemorrhoidal disease | |
| US4897404A (en) | Anti-infective methods and compositions | |
| US11951082B2 (en) | Composition of chlorhexidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |